Surgical treatment for pelvic bone metastatic disease from renal cell carcinoma
- PMID: 37144636
- DOI: 10.1002/jso.27305
Surgical treatment for pelvic bone metastatic disease from renal cell carcinoma
Abstract
Introduction: Pelvic bone metastases from renal cell carcinoma (RCC) are challenging due to their destructive pattern, poor response to radiotherapy and hypervascularity. The purpose of our study was to review a series of patients undergoing surgical treatment with the aim to investigate: 1) survival; 2) local disease control; and 3) complications.
Methods: A series of 16 patients was reviewed. A curettage procedure was performed on 12 patients. In eight the lesion involved the acetabulum; a cemented hip arthroplasty with cage was performed in seven; a flail hip in one. Four patients received a resection; in two cases with acetabular involvement, reconstruction was performed with a custom-made prosthesis and with an allograft and prosthesis.
Results: Disease-specific survival accounted for 70% at 3 years and 41% at 5 years. Only one local tumor progression after curettage occurred. Revision surgery (flail hip) was necessary for deep infection of the custom-made prosthesis.
Conclusion: A prolonged survival in patients affected by bone metastatic disease from RCC can justify also major surgical procedures. Due to a low local progression rate after intralesional procedures, curettage, cement and a total hip arthroplasty with cage, when feasible, should be considered as an alternative to more demanding surgeries like resections and reconstructions.
Level of evidence (oxford): Level 4.
Keywords: bone metastatic disease; pelvic metastases; pelvic surgery; renal cell carcinoma.
© 2023 Wiley Periodicals LLC.
References
REFERENCES
-
- McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000;27:115-123.
-
- Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316-3322. doi:10.1200/JCO.2004.09.104
-
- Han KR, Pantuck AJ, Bui MHT, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314-319. doi:10.1016/s0090-4295(02)02163-5
-
- Zekri J, Ahmed N, Coleman R, Hancock B. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;9:379-382. doi:10.3892/ijo.19.2.379
-
- Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2011;22:794-800. doi:10.1093/annonc/mdq554
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
